Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Holdings Lifted by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. grew its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 56,155 shares of the medical equipment provider’s stock after acquiring an additional 1,122 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Intuitive Surgical were worth $27,587,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Ridgewood Investments LLC bought a new stake in shares of Intuitive Surgical in the 2nd quarter worth about $26,000. Godsey & Gibb Inc. lifted its position in Intuitive Surgical by 140.0% during the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 35 shares during the period. Creekmur Asset Management LLC lifted its position in Intuitive Surgical by 200.0% during the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 42 shares during the period. LGT Financial Advisors LLC boosted its stake in Intuitive Surgical by 415.4% during the 2nd quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 54 shares during the last quarter. Finally, Delos Wealth Advisors LLC boosted its stake in Intuitive Surgical by 380.0% during the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 57 shares during the last quarter. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Trading Down 0.1 %

NASDAQ:ISRG traded down $0.53 on Wednesday, reaching $536.54. 101,357 shares of the stock traded hands, compared to its average volume of 1,453,387. The firm has a market capitalization of $191.10 billion, a price-to-earnings ratio of 86.35, a price-to-earnings-growth ratio of 5.27 and a beta of 1.39. The company’s 50 day moving average is $495.85 and its 200-day moving average is $455.08. Intuitive Surgical, Inc. has a 1-year low of $287.98 and a 1-year high of $542.59.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.32. The firm had revenue of $2.04 billion for the quarter, compared to analysts’ expectations of $2.01 billion. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. On average, equities research analysts forecast that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

Insider Buying and Selling

In other news, General Counsel Gary Loeb sold 300 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $475.00, for a total transaction of $142,500.00. Following the completion of the sale, the general counsel now directly owns 1,595 shares of the company’s stock, valued at $757,625. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Intuitive Surgical news, EVP Robert Desantis sold 396 shares of Intuitive Surgical stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $486.88, for a total transaction of $192,804.48. Following the completion of the transaction, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,680,761.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Gary Loeb sold 300 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $475.00, for a total transaction of $142,500.00. Following the completion of the sale, the general counsel now directly owns 1,595 shares in the company, valued at approximately $757,625. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 91,178 shares of company stock worth $45,897,071 in the last ninety days. Corporate insiders own 0.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. The Goldman Sachs Group set a $604.00 target price on shares of Intuitive Surgical in a report on Friday, October 18th. Citigroup upped their price objective on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Truist Financial boosted their target price on shares of Intuitive Surgical from $520.00 to $570.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Finally, Evercore ISI reissued a “cautious” rating on shares of Intuitive Surgical in a research report on Friday, October 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $513.74.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.